Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma

Jun Cao; Jun Cao; Yaner Yu; Yangkun Zhou; Qing Ji; Wenkang Qian; Dongdong Jia; Gu Jin; Yajun Qi; Xin Li; Ningning Li; Tao Li; Meiyu Fang; Hongchuan Jin

doi:10.3389/fonc.2022.942258

Frontiers in Oncology (Oct 2022)

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma

Jun Cao,
Jun Cao,
Yaner Yu,
Yangkun Zhou,
Qing Ji,
Wenkang Qian,
Dongdong Jia,
Gu Jin,
Yajun Qi,
Xin Li,
Ningning Li,
Tao Li,
Meiyu Fang,
Hongchuan Jin

Affiliations

Jun Cao: Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China
Jun Cao: Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Department of Rare and Head and Neck Oncology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China
Yaner Yu: Department of Radiation Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Yangkun Zhou: School of Life Sciences and Technology, Southeast University, Nanjing, China
Qing Ji: Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Department of Rare and Head and Neck Oncology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China
Wenkang Qian: Department of Bone and Soft Tissue Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China
Dongdong Jia: Department of Bone and Soft Tissue Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China
Gu Jin: Department of Bone and Soft Tissue Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China
Yajun Qi: Department of Pharmacy, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China
Xin Li: Department of Nuclear Medicine, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China
Ningning Li: Department of Pathology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China
Tao Li: Department of Bone and Soft Tissue Surgery, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China
Meiyu Fang: Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Department of Rare and Head and Neck Oncology, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China
Hongchuan Jin: Sir Run Run Shaw Hospital, Medical School of Zhejiang University, Hangzhou, China

DOI: https://doi.org/10.3389/fonc.2022.942258
Journal volume & issue: Vol. 12

Abstract

Read online

IntroductionSinonasal mucosal melanoma (SNMM) originates from melanocytes. Currently, the main treatment methods, including surgery, radiotherapy and chemotherapy, have little effect on the recurrence and metastasis of SNMM. However, targeted therapy may be a breakthrough in treating SNMM.MethodsA SNMM patient with ROS1 fusion received 250mg Crizotinib capsule (2 times a day, 1 tablet each time) therapy.ResultsThe patient achieved partial remission after 4 months of treatment and complete remission after 8 months of treatment.ConclusionOur findings suggest that crizotinib can be an option to improve overall survival and quality of life of patients with metastatic ROS1-fusion SNMM. We believe that our report will provide insights for the application of crizotini in the treatment of melanoma.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords